IDEXX Laboratories (IDXX) vs Neogen (NEOG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neogen (NEOG) has outperformed IDEXX Laboratories (IDXX) over the past year, gaining 101.2% versus a loss of 18.5%. Over five years, IDXX leads with a -19.2% price change compared with -71.5% for NEOG. IDEXX Laboratories is the larger company by market cap ($40.81 billion vs $2.59 billion), about 15.8 times the size.
On valuation, IDEXX Laboratories trades at a lower forward P/E (30.9x vs 31.2x for Neogen). IDEXX Laboratories converts more of its revenue into profit, with a net margin of 24.6% versus -0.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IDXX | NEOG |
|---|---|---|
| Share price | $518.00 | $11.85 |
| Market cap | $40.81B | $2.59B |
| 1-day change | +0.95% | +1.20% |
| YTD return | -24.15% | +67.53% |
| 1-year return | -18.54% | +101.20% |
| 5-year return | -19.21% | -71.47% |
| P/E ratio (TTM) | 36.40 | — |
| Forward P/E | 30.95 | 31.18 |
| EPS (TTM) | $14.23 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.30B | $870.40M |
| Revenue growth (YoY) | +10.42% | -2.72% |
| Net income (latest FY) | $1.06B | $-7.90M |
| Gross margin | 61.80% | 46.93% |
| Operating margin | 31.60% | -2.48% |
| Net margin | 24.62% | -0.91% |
| 52-week high | $769.98 | $14.26 |
| 52-week low | $500.61 | $5.37 |
| Distance from 52-week high | -32.73% | -16.90% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +35.39% | +18.14% |
| Average volume | 553.95K | 3.14M |
| Shares outstanding | 78.78M | 218.31M |
| Employees | 11,000 | 2,636 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IDEXX Laboratories is about 15.8 times larger than Neogen by market value ($40.81B vs $2.59B).
- NEOG has outperformed IDXX by 119.7 percentage points over the past year.
- IDEXX Laboratories is more profitable, keeping 24.6 cents of every revenue dollar as net income versus -0.9 cents for Neogen.
- IDEXX Laboratories grew revenue faster in its latest fiscal year (+10.42% vs -2.72%).
About IDEXX Laboratories
IDXX stock →IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 11,000 employees
About Neogen
NEOG stock →Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,636 employees
IDXX vs NEOG FAQ
Which is bigger, IDEXX Laboratories or Neogen?
IDEXX Laboratories (IDXX) is larger, with a market capitalization of $40.81B compared with $2.59B for Neogen (NEOG).
Which stock has performed better over the past year, IDXX or NEOG?
NEOG returned +101.20% over the past 12 months, compared with -18.54% for IDXX (price return, excluding dividends). Past performance does not predict future results.
Are IDEXX Laboratories and Neogen in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.